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Background:  Despite advances in understanding the pathophysiology and treatment of heart failure (HF), hospitalization rates and costs 
have relentlessly increased. Recently, implantable hemodynamic monitors have been studied to circumvent clinical methods of detecting 
decompensation, which have proved unreliable and ineffective in preventing hospitalization. We systematically reviewed the evidence on 
the efficacy of implantable continuous hemodynamic monitor (ICHM) guided HF therapy compared to standard HF monitoring and therapy 
in reducing hospitalization.
methods:  Relevant studies were identified through electronic searches of MEDLINE, EMBASE, Cochrane and clinicaltrials.gov from 
commencement till June 2014. Randomized controlled clinical trials looking at ICHM in patients with heart failure with NYHA class ≥II 
were included. Study specific odds ratios were calculated and combined using random-effects model. Between-study heterogeneity was 
assessed using the I2-statistic.
results:  Three RCTs, enrolling 1,224 patients were included. Of 606 patients in the ICHM arm, there were 228 HF hospitalizations in 135 
patients compared to 298 HF hospitalizations in 180 of 618 patients in the control arm (OR 0.64; 95% CI 0.51-0.81, I2 = 39%, p< 0.0002). 
The device complication rate was 5.99%. There were 12 hypovolemia events in 12 patients of the 336 patients in the ICHM guided therapy 
group, compared to 15 events in 13 patients in 338 patients in control arm (OR 0.81 95% CI0.35 - 1.75 I2 0%, p = 0.59)
conclusion:  ICHM-guided medical treatment, compared to standard treatment in patients with chronic heart failure, reduces heart failure 
hospitalizations withoutsignificantly increasing the risk of over-diuresis. This effect was found to be independent of sensor location. The 
results however, need to be interpreted with caution given industry involvement in these studies, the different strategies employed and 
close monitoring and follow up within the setting of a clinical trial. Future studies should be geared towards developing and validating 
treatment algorithms to guide ICHM directed patient self-management. Furthermore, impact of adherence in real world patients need to be 
evaluated.
